Genmab — Juli 2019
-
Jeg er på mandag. Det afbalancerer det nok lidt.
-
New trial
- Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial (DARALLO) - https://clinicaltrials.gov/ct2/show/NCT04024384
-
Husk nu at jeg er biased.
-
http://www.globenewswire.com/news-release/2019/07/19/1885137/0/en/Genmab-Announces-Submission-of-Extension-of-Marketing-Authorization-to-European-Medicines-Agency-for-Subcutaneous-Formulation-of-Daratumumab.html Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for Subcutaneous Formulation of Daratumumab
-
Ditto herfra.
-
Hvis der er en marketmaker på vil kurserne hurtigt blive ens. Det fiskede jeg lidt efter i med mine spørgsmål i går.
-
Det ender jo med at vi følger mere med i USA kursen end i den danske
-
-
Næsten fire milliarder kroner i kassen. Spændende at se hvad de skal bruges til.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind